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The inhibition of proteinase activity by members of
the serine proteinase inhibitor (serpin) family is a crit-
ical regulatory mechanism for a variety of biological
processes. Once formed, the serpin enzyme complexes
(SECs) are removed from the circulation by a hepatic
receptor. The present study suggests that this receptor
is very likely the low density lipoprotein receptor-re-
lated protein (LRP), a prominent liver receptor. In vitro
binding studies revealed that antithrombin III
(ATIII)zthrombin, heparin cofactor II (HCII)zthrombin,
and a1-antitrypsin (a1AT)ztrypsin bound to purified
LRP, and their binding was inhibited by the 39-kDa
receptor-associated protein (RAP), an antagonist of
LRP-ligand binding activity. In contrast, native or mod-
ified forms of the inhibitors were unable to bind to LRP.
Mouse embryonic fibroblasts, which express LRP, medi-
ate the cellular internalization leading to degradation of
these SECs, while mouse fibroblasts genetically defi-
cient in LRP showed no capacity to internalize and de-
grade these complexes. SECs were also degraded by
HepG2 cells, and this process was inhibited by LRP an-
tibodies, RAP, and chloroquine. The cellular-mediated
uptake and degradation was specific for SECs; native or
modified forms of the inhibitors were not internalized
and degraded. Finally, in vivo clearance studies in rats
demonstrated that RAP inhibited the clearance of
ATIIIz125I-thrombin complexes from the circulation. To-
gether, these results indicate that LRP functions as a
liver receptor responsible for the plasma clearance of
SECs.
Serine proteinase inhibitors (serpins) are a supergene family
comprised of more than 40 members (Carrell and Travis, 1985).
Most serpins function to inhibit serine proteinases through
the formation of a stable serpin-enzyme complex (SEC)1
(Laskowski and Kato, 1980, Travis and Salvesen, 1983); how-
ever, some members such as angiotensinogen and ovalbumin
are unable to inhibit proteinases (Doolittle, 1983; Hunt and
Dayhoff, 1980). The inhibitory serpins are found in three dis-
tinct structural conformations; native (active inhibitor),
cleaved (an inactive inhibitor generated after cleavage of its
reactive center loop), or complexed with a proteinase. The in-
hibitory action of serpins affect a broad range of biological
processes including coagulation, fibrinolysis, inflammation,
connective tissue turnover, complement activation, and phag-
ocytosis (for reviews, see Travis and Salvesen (1983), Bjork and
Danielsson (1986), and Carrell and Travis (1985)).
a1-Antitrypsin (a1AT, also referred to as a1-proteinase inhib-
itor) is the prototypic member of the serpin family and primar-
ily acts to inhibit neutrophil elastase and proteinase 3 (PR3)
(Travis and Salvesen, 1982; Carrell and Travis, 1985; Rao et
al., 1991). Neutrophil elastase and PR3 degrade connective
tissue matrix proteins, and both enzymes can induce emphy-
sema in animal models (Janoff et al., 1977; Senior et al., 1977;
Kao et al., 1988). a1AT is present in high concentration in the
plasma (.25 mM) and protects the connective tissue-rich lung
against excessive proteolysis through its inhibitory action on
neutrophil elastase and PR3. The protection of lung tissue by
a1AT is evidenced by studies that have genetically linked de-
creased functional levels of a1AT with the early onset of pul-
monary emphysema (Laurell and Eriksson, 1963; Travis and
Salvesen, 1983; Carrell, 1986).
Antithrombin III (ATIII), a serpin with extensive sequence
similarity to a1AT, plays a major role in hemostasis by acting
as the principle physiological inhibitor of thrombin and coagu-
lation Factor Xa (for reviews see Bjork and Danielsson (1986),
Bjork et al. (1989), and Olson and Bjork (1992)). This inhibitor
is present in high concentration in the plasma (5 mM), and its
importance is underscored by the observation that reduced
functional levels of ATIII are associated with increased risks of
thromboembolic disorders (Edeburg, 1965; Lane et al., 1991).
Heparin cofactor II (HCII) is a 65,000-dalton inhibitor of
thrombin, cathepsin G, and chymotrypsin (Tollefsen et al.,
1982; Church and Hoffman, 1994; Church et al., 1995) and is
present in the human plasma at a concentration of 1.4 mM. Like
ATIII, its ability to react with target proteinases is greatly
accelerated in the presence of heparin. Individuals exhibiting
low levels of HCII but having normal levels of ATIII display
thrombotic tendencies (Tran et al., 1985; Sie et al., 1985),
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suggesting that HCII, like ATIII, is an important inhibitor of
thrombin in vivo.
An important feature of serpin metabolism was originally
identified when Lollar et al. (1980) showed that 125I-thrombin
in complex with ATIII was rapidly cleared from the circulation
of rabbits by the liver. Additional studies by several groups
(Bauer et al., 1982; Fuchs et al., 1982; Pratt et al., 1988) have
demonstrated that the liver mediates rapid clearance of com-
plexes of ATIIIzthrombin, HCIIzthrombin, a1ATztrypsin, and
a1ATzelastase from the circulation. Further, these complexes
could compete for one another’s clearance, indicating that the
plasma elimination of these SECs was occurring via a common
receptor pathway. Mast et al. (1991) showed that the kinetics of
plasma elimination of the native and cleaved inhibitors were
10–50 times slower than that of the complexed inhibitors,
suggesting that the liver receptor might preferentially clear the
SEC as opposed to the free serpin.
The low density lipoprotein receptor (LDLR) and low density
lipoprotein receptor-related protein (LRP) are two prominent
hepatic receptors that are members of the LDLR superfamily.
This receptor family also includes the very low density lipopro-
tein receptor and glycoprotein 330 (gp330). LRP is expressed in
many tissues and cell types (Moestrup et al., 1992) and is
present in high abundance in the liver. The requirement for
LRP expression during development was demonstrated when
targeted disruption of the LRP gene resulted in termination of
the null embryos at day 13.5 during development (Herz et al.,
1992). LRP interacts with numerous ligands and is thought to
play key roles in both lipoprotein metabolism and proteinase
regulation (for reviews, see Krieger and Herz (1994), Strick-
land et al. (1994, 1995), and Moestrup (1994)).
In addition to mediating the catabolism of a2-macroglobulin
(a2M)-proteinase complexes (Ashcom et al., 1990), LRP also
binds to several SECs, including elastaseza1AT (Poller et al.,
1995), urinary-type plasminogen activator (uPA)zPAI-1 (Herz
et al., 1992; Nykjaer et al., 1992), and tissue plasminogen
activator zPAI-1 (Orth et al., 1992). However, the receptor re-
sponsible for the hepatic catabolism of a number of other pre-
dominant SECs remained obscure. Studies were therefore ini-
tiated to determine if LRP could interact with those SECs. In
this report we demonstrate that LRP binds directly to com-
plexes of ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin,
can mediate their cellular uptake and degradation, and ap-
pears responsible for their in vivo clearance from the
circulation.
EXPERIMENTAL PROCEDURES
Proteins—LRP was isolated from human placenta as described by
Ashcom et al. (1990). Human RAP, expressed in bacteria as a fusion
protein with glutathione S-transferase, was prepared and purified as
described previously (Williams et al., 1992). a2M was purified from
human plasma by zinc-chelate chromatography as described previously
(Ashcom et al., 1990). a2Mzmethylamine, designated (a2M*), was pre-
pared by incubation of native a2M with 200 mM methylamine (Sigma)
for 30 min at 25 °C followed by dialysis against Tris-buffered saline
(TBS). HCII was purified from human plasma as described previously
(Griffith et al., 1985). Antithrombin III was isolated from human
plasma as described (Miller-Andersson et al., 1974). a1AT was pur-
chased from Athens Research and Technology (Athens, GA). Inhibitors
inactivated by cleavage of the reactive center loop, without complex
formation, are referred to as modified or cleaved inhibitors. Modified
inhibitors were prepared by incubation of inhibitor in TBS (1 mg/ml)
with 100 ml of activated immobilized papain-Sepharose (Pierce) for 30
min at 25 °C. To monitor the efficiency of papain to cleave inhibitors,
cleaved preparations were tested for their ability to inhibit target
proteinases. In addition, SDS-polyacrylamide gel electrophoresis anal-
ysis of the inhibitors revealed a shift in mobility on 8–16% polyacryl-
amide gradient gels (Novex, San Diego, CA) as compared with native
inhibitors and also showed that papain treatment did not result in
excess proteolysis of the cleaved inhibitors. Thrombin (a-form) was
purchased from Enzyme Research Laboratories (South Bend, IN). Tryp-
sin was purchased from Sigma. To prepare complexes of ATIIIzthrombin
and HCIIzthrombin, the enzyme and inhibitor were combined in a 1:2
molar ratio and were incubated for 30 min at 25 °C. Complexes of
a1ATztrypsin were prepared by incubation of trypsin and a1AT at a 1:2
molar ratio for 5 min at 25 °C, followed by addition of soybean trypsin
inhibitor (Sigma) (in a molar amount equal to that of trypsin added) to
inhibit any residual trypsin activity. uPA was provided by Jack Henkin
(Abbott Park, IL). Active PAI-1 was purchased from Molecular Innova-
tions (Royal Oak, MI). Complexes of uPAzPAI-1 were prepared by incu-
bation of a 1:1 molar ratio of active PAI-1 with uPA for 30 min at 25 °C.
Proteins were labeled with [125I]iodine to a specific activity ranging
from 2 to 10 mCi/mg of protein using IODOGEN (Pierce). Bovine serum
albumin, fraction V (BSA) was purchased from Sigma.
Antibodies—A rabbit polyclonal antibody to the 515-kDa heavy chain
of LRP (R777) and another one to a synthetic peptide from the cyto-
plasmic domain of the 85-kDa light chain of LRP (R704) have been
described elsewhere (Kounnas et al., 1992). R777 antibodies were affin-
ity-purified on a column of LRP-Sepharose. R704 antibodies were pu-
rified on protein G-Sepharose (Pharmacia Biotech Inc.). Both of the
rabbit antibody preparations were dialyzed against isotonic PBS, heat-
inactivated for 30 min at 56 °C, and filtered with a 0.45 mM Acrodisc
(Corning, Corning, NY) prior to use in cell assays. The mouse mono-
clonal antibody to LRP, designated 8G1, has been described (Strickland
et al., 1990).
Solid-phase Binding Assays—Enzyme-linked immunosorbent assays
(ELISA) were performed as detailed elsewhere (Kounnas et al., 1993).
Briefly, microtiter wells were coated with the native, cleaved, or com-
plexed forms of ATIII, HCII, or a1AT (prepared as described under
“Proteins”) at 10 mg/ml in TBS, pH 8.0, for 4 h at 37 °C, blocked with 3%
BSA, TBS, pH 8.0, then incubated with various concentrations of LRP
(0.6–150 nM) in 3% BSA, TBS, 5 mM CaCl2, 0.05% Tween-20 for 18 h at
4 °C. For ELISAs measuring the effects of RAP, coated wells were
incubated with 20 nM LRP in the presence of increasing concentrations
of RAP (0.2–450 nM). LRP binding was detected with the mouse mono-
clonal antibody 8G1.
Cells—Human hepatocellular carcinoma (HepG2, ATCC HB 8065)
cells were obtained from the American Type Culture Collection (ATCC,
Rockville, MD) and were grown in Eagle’s minimal essential medium
containing 10% bovine calf serum (HyClone Laboratories, Logan, UT),
100 units/ml penicillin (Life Technologies, Inc.), 100 mg/ml streptomycin
(Life Technologies, Inc.), and 1% L-glutamine (Life Technologies, Inc.).
A normal mouse embryonal fibroblast line (MEF) and a mouse embry-
onal fibroblast cell line that is deficient in LRP biosynthesis (PEA13)
were obtained from Dr. Joachim Herz (University of Texas Southwest-
ern Medical Center, Dallas, TX) and maintained as described by Will-
now and Herz (1994).
Cell-mediated Ligand Internalization and Degradation Assays—
Cells were seeded into 12-well dishes (Corning) at 2–3 3 105 cells/well
and allowed to grow for 24 h at 37 °C, 5% CO2. Cellular internalization
and degradation assays were conducted according to Kounnas et al.
(1995a). Prior to performing the assays, cultured cells were washed
with medium and incubated in medium containing 1% Nutridoma
(Boehringer Manneheim), 20 mM Hepes, penicillin/streptomycin, and
1.5% BSA (assay medium). For assays with HepG2 cells, radiolabeled
serpin-enzyme complexes (10 nM) in assay medium were incubated with
cells for 18 h at 37 °C in the presence of RAP (1 mM), LRP antibodies
(100 mg/ml), or chloroquine (0.1 mM, Sigma). For assays using antibod-
ies, cultured cells were preincubated for 1 h at 37 °C with assay medium
containing antibodies. Antibodies (100 mg/ml) were also included during
the cellular assay. For assays utilizing cultured fibroblasts, 125I-pro-
teins (5–10 nM) were added in assay medium either alone or in the
presence of RAP (1 mM) for the indicated times. Total radioactivity
secreted in the cell culture medium that was soluble in 10% trichloro-
acetic acid was corrected for non-cellular mediated degradation by
subtracting the amount of degradation that occurred in parallel wells
lacking cells. The amount of radiolabeled ligand that was internalized
by cells was defined as the amount of radioactivity that remained
associated with the cell pellet following trypsin-EDTA, proteinase K
(Sigma) treatment (Chappell et al., 1992).
Clearance of ATIIIz125I-Thrombin from the Plasma of Rats—Sprague-
Dawley rats (200 g) were anesthetized with ketamine (100 mg/ml)/
xylazine (20 mg/ml) at a dose of 90 mg/kg ketamine, 8 mg/kg xylazine.
A bolus of 500 ml of ATIIIz125I-thrombin (100 nM) in the presence or
absence of RAP (110 mM) was injected into the tail vein over a period of
approximately 15 s. At selected time intervals following injection (1, 5,
10, and 20 min), blood (200 ml) was collected from the vena cava into 10
ml of 0.5 M EDTA, and an aliquot (50 ml) was counted for its 125I content.
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In those experiments examining the clearance of 125I-a2M*, a bolus of
500 ml of 125I-a2M (10 nM) in the presence or absence of RAP (32 mM) was
injected. The initial time point, taken 1 min after injection, was consid-
ered to represent 100% radioactivity in the circulation. The clearance of
each preparation was examined in two rats and the results averaged.
RESULTS
ATIIIzThrombin, HCIIzThrombin, and a1ATzTrypsin Bind to
LRP—The ability of LRP to bind to native, cleaved, or com-
plexed forms of ATIII, HCII, and a1AT was measured using an
ELISA. As shown in Fig. 1, LRP binds to ATIIIzthrombin (panel
A), HCIIzthrombin (panel B), and a1ATztrypsin (panel C), while
no detectable binding to the native or cleaved forms of ATIII
(panel A), HCII (panel B), and a1AT (panel C) was observed.
The lack of saturation in these assays indicates that the affin-
ity of LRP for these SECs is weaker than that measured for
other LRP ligands. Apparent half-saturation values measured
for the binding interaction of these complexes with LRP are
estimated to range from 80 to 120 nM.
Since RAP is known to inhibit the binding of ligands to LRP
(Herz et al., 1991), binding assays were performed to test the
effect of RAP on the binding of LRP to ATIIIzthrombin,
HCIIzthrombin, and a1ATztrypsin. Fig. 2 depicts an ELISA in
which LRP was incubated with serpin-proteinase-coated wells
in the presence of increasing concentrations of RAP. These data
demonstrate that RAP is capable of competing for the binding
of these SECs to LRP.
Efficient Uptake and Degradation of Complexes of 125I-
ThrombinzATIII, 125I-ThrombinzHCII, and 125I-Trypsinza1AT
Is Abolished in Fibroblasts Lacking LRP—Cellular uptake and
degradation experiments in mouse embryonal fibroblasts
(MEF) which express LRP and in a mutant MEF cell line that
lacks LRP (PEA13) were conducted in order to determine the
role of LRP in the catabolism of 125I-labeled complexes of
ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin. For these
experiments, trypsin or a-thrombin were labeled with 125I-
iodine and then complexed to an inhibitor. As shown in Fig. 3,
little or no detectable free enzyme remained after addition of
inhibitors. Fig. 4 shows that LRP-expressing MEF cells, but not
LRP-deficient PEA13 cells, were capable of internalizing and
degrading complexes of ATIIIz125I-thrombin (panels A and B),
HCIIz125I-thrombin (panels C and D), and a1ATz
125I-trypsin
(panels E and F). Further, in MEF cells, the uptake and deg-
radation of labeled complexes was inhibited by RAP, an antag-
onist of the binding of LRP to ATIIIzthrombin, HCIIzthrombin,
and a1ATztrypsin (see Fig. 2). The ability of RAP to block
uptake and degradation of 125I-SECs in LRP-expressing cells
and the inability of LRP-deficient cells to mediate SEC uptake
and degradation point to LRP as a mediator of the endocytosis
of SECs.
LRP Antibodies Inhibit the Degradation of ATIIIz125I-Throm-
bin, HCIIz125I-Thrombin, and a1ATz
125I-Trypsin in HepG2
Cells—To further implicate LRP in mediating the uptake and
degradation of ATIIIz125I-thrombin, HCIIz125I-thrombin, and
FIG. 2. RAP inhibits the binding of LRP to complexes of
ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin. Wells coated
with ATIIIzthrombin (å), HCIIzthrombin (f), a1ATztrypsin (l), or BSA
(E) were incubated with 20 nM LRP in the presence of increasing
concentrations of RAP (0.2–450 nM) for 18 h at 4 °C. Following incuba-
tion, microtiter wells were washed and the bound LRP was detected
with the LRP monoclonal antibody 8G1.
FIG. 3. SDS-polyacrylamide gel electrophoresis analysis of ser-
pin complexes. Thrombin and trypsin were labeled with 125I-iodine
and complexed to inhibitors as described under “Experimental Proce-
dures.” Proteins were electrophoresed on 8–16% polyacrylamide gradi-
ent gels (Novex, San Diego, CA) under non-reducing conditions,
wrapped in plastic, and exposed to x-ray film for 30 min. The migration
position of the molecular mass standards indicated were determined
using Novex prestained rainbow standard proteins. Lane 1, 125I-
trypsinza1AT; lane 2,
125I-trypsin; lane 3, 125I-thrombinzHCII; lane 4,
125I-thrombinzATIII; lane 5, 125I-thrombin.
FIG. 1. Binding of LRP to ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin. In panel A, increasing concentrations of LRP (0.6–150 nM)
were incubated for 18 h at 4 °C with wells coated with native ATIII (E), cleaved ATIII (f), ATIIIzthrombin (l), or BSA (M). Panel B, native HCII
(E), cleaved HCII (f), HCIIzthrombin (l), and BSA (M). Panel C, native a1AT (E), cleaved a1AT (f), a1ATztrypsin (l), and BSA (M). Following
incubation, wells were washed and bound LRP detected with the LRP monoclonal antibody 8G1.
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a1ATz
125I-trypsin complexes, the effect of LRP antibodies on
the degradation of 125I-labeled SECs by HepG2 cells was de-
termined. Fig. 5 shows that RAP, LRP antibodies, and chloro-
quine (a drug that blocks lysosomal degradation) inhibit the
degradation of ATIIIz125I-thrombin (panel A), HCIIz125I-throm-
bin (panel B), and a1ATz
125I-trypsin (panel C). In each case,
control antibodies had little effect. These data demonstrate
that LRP is capable of mediating the endocytosis leading to
lysosomal degradation of labeled ATIIIzthrombin, HCIIz
thrombin, and a1ATztrypsin in HepG2 cells, raising the possi-
bility that LRP can function in vivo to mediate the liver clear-
ance of these complexes.
The Uptake and Degradation of 125I-ATIII, 125I-HCII, and
125I-a1AT Requires Complex Formation with an Enzyme—Pre-
vious studies examining the clearance of 125I-labeled SECs
from plasma in a mouse model have shown that while the
complexed form of ATIII, HCII, and a1AT are cleared rapidly
by hepatocytes, the clearance of the native and cleaved inhib-
itors is slow (Mast et al., 1991). We, therefore performed assays
to investigate the LRP-mediated cellular endocytosis of 125I-
labeled inhibitors in the native, cleaved, or complexed forms.
Fig. 6 shows the uptake of 125I-ATIII (native, cleaved, and
thrombin complexed) in MEF (LRP-expressing cells) (panel A)
and PEA13 (LRP-deficient cells) (panel B), 125I-HCII (native,
cleaved, and thrombin complexed) in MEF and PEA13 cells
(panels C and D, respectively), and 125I-a1AT (native, cleaved,
and complexed to trypsin) in MEF and PEA13 cells (panels E
and F, respectively). These data demonstrate that the labeled
inhibitors alone (native or cleaved) are not endocytosed by
mouse fibroblasts. However, complexes of 125I-ATIIIzthrombin,
125I-HCIIzthrombin, and 125I-a1ATztrypsin are internalized ef-
ficiently by LRP-expressing MEF cells but not the mutant
LRP-deficient PEA13 cells and this process is inhibited by
RAP. Further, these complexes are efficiently degraded in LRP-
expressing cells (but not LRP-deficient cells) in a RAP-depend-
ent manner with similar kinetics as shown in Fig. 4 (data not
shown). These data reveal that proteinase complex formation of
ATIII, HCII, and a1AT is required for LRP-mediated
endocytosis.
Comparative Degradation of Different LRP Ligands by
Mouse Fibroblasts—Complexes of uPAzPAI-1 bind to LRP with
an affinity constant of 1 nM (Nykjaer et al., 1994), while com-
plexes of ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin
bind to LRP with estimated affinities of 80–120 nM. This ob-
servation prompted us to compare the amounts of 125I-labeled
SECs that were degraded by cells in an LRP-dependent man-
ner. The first experiments were designed to determine the
relative levels of 125I-labeled SEC degraded by mouse fibro-
FIG. 4. LRP-deficient fibroblasts do not internalize and de-
grade complexes of 125I-thrombinzATIII, 125I-thrombinzHCII, and
125I-trypsinza1AT.Wells containing 2 3 10
5 MEF (LRP-expressing) or
PEA13 (LRP-deficient) cells were incubated with 125I-enzyme-serpin
complexes (10 nM) for selected time intervals at 37 °C in the presence
and absence of RAP (1 mM). At the indicated times, the amount of
radioligand internalized by the cell and the levels of degraded radioli-
gand secreted into the cell medium were determined as described under
“Experimental Procedures.” Panels show internalization and degrada-
tion of ATIIIz125I-thrombin (A and B), HCIIz125I-thrombin (C and D),
and a1ATz
125I-trypsin (E and F), respectively. The data shown are
representative of three experiments, each performed in duplicate.
FIG. 5. LRP antibodies inhibit 125I-thrombinzATIII, 125I-thrombinzHCII, and 125I-trypsinza1AT degradation by HepG2 cells. Wells
containing 2 3 105 HepG2 cells were incubated for 18 h at 37 °C with 125I-labeled complexes (10 nM) in the presence of affinity-purified anti-LRP
IgG (100 mg/ml), control IgG against the cytoplasmic domain of LRP (100 mg/ml), chloroquine (0.1 mM), or RAP (1 mM). Panels show degradation
data of 125I-ATIIIzthrombin (A), 125I-HCIIzthrombin (B), and 125I-a1ATztrypsin (C). Plotted values represent means of duplicate values.
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blasts expressing LRP (MEF) using a ligand concentration of 1
nM. These data are shown in Fig. 7 (panel A) and reveal that the
amount of uPAzPAI-1 degraded in an LRP-dependent manner
(as determined by the ability of RAP to compete) is approxi-
mately 10-fold greater than that of the other SECs examined
and approximately 3-fold greater than a2M*, another LRP
ligand. Further experiments were conducted using a dose of
125I-labeled ligand (0.6–150 for ATIIIzthrombin, HCIIzthrombin,
and a1ATztrypsin (panel B) and 0.6–16.6 nM for uPAzPAI-1
(panel C)). From these data it is evident that at a given con-
centration of 125I-labeled SEC, approximately 10-fold more
uPAzPAI-1 is degraded when compared to the other SECs. For
example, at a ligand concentration of 15 nM, approximately
2000 fmol of uPAzPAI-1 is degraded in 18 h, an amount that is
achieved when a 10-fold higher concentration (150 nM) of 125I-
labeled ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin is
used. These data are consistent with the higher affinity of LRP
for uPAzPAI-1 (1 nM) and a lower affinity of LRP for ATIIIz
thrombin, HCIIzthrombin, and a1ATztrypsin (approximately
80–120 nM).
Effect of RAP on the Plasma Clearance of 125I-a2M* and
ATIII-125I-Thrombin Complexes—To evaluate the role of LRP
in mediating the plasma clearance of SECs, the effect of RAP
on the clearance rate of a representative SEC, the ATIII-throm-
bin complex, was measured. RAP is known to have a pro-
nounced effect on the removal of 125I-a2M* from the mouse
circulation (Willnow et al. 1994), and thus 125I-a2M* was used
as a control for these experiments. The results, shown in Fig. 8,
demonstrate that when co-injected with the ligand, RAP sig-
nificantly delays the clearance of 125I-a2M* (Fig. 8A) and
ATIII-125I-thrombin complexes (Fig. 8B) from the rat circula-
tion. These studies indicate that a RAP-sensitive hepatic re-
ceptor, most likely LRP, plays a major role in the removal of
ATIII-125I-thrombin complexes from the circulation.
DISCUSSION
The existence of a hepatic receptor that is responsible for
binding and removing SECs from the plasma was demon-
strated in early studies (Pizzo and Gonias, 1984; Shifman and
Pizzo, 1982; Imber and Pizzo, 1981; Fuchs et al., 1982; Pratt et al.,
1988) in which labeled SECs (ATIIIzthrombin, HCIIzthrombin,
a1ATztrypsin, and a1ATzelastase) were shown to be rapidly
cleared by the liver (half-lives 5 3, 10, 15, and 20 min, respec-
tively). These complexes apparently all bound to the same
receptor, since they were able to cross-compete with one an-
other (Pratt et al., 1988). However, clearance of these molecules
was not competed with high concentrations of a2Mzproteinase
complexes (Fuchs et al., 1982). The clearance mechanism ap-
pears specific for the enzyme-complexed form of these serpins,
since studies by Mast et al. (1991) demonstrated that the clear-
ance of native and cleaved forms of ATIII, HCII, and a1AT
occurred at a considerably slower rate (half-lives . 1 h) than
the proteinase-complexed serpins.
The data presented in the current study suggest that LRP is
the hepatic receptor responsible for the clearance of these com-
plexes. This conclusion is supported by several independent
lines of evidence. First of all, we demonstrated that purified
LRP can directly bind to several SECs (ATIIIzthrombin,
HCIIzthrombin, and a1ATztrypsin) coated on microtiter wells,
and that the binding is competed by RAP. Second, SECs are
internalized and degraded in mouse fibroblasts that express
LRP, but not in mouse fibroblasts genetically deficient in LRP.
Third, we demonstrated that LRP antagonists, RAP and LRP
antibodies, blocked the cellular uptake and degradation of 125I-
labeled ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin.
Fourth, our studies have shown that the interaction of SECs
with LRP has properties expected of the hepatic clearance
mechanism; LRP does not recognize the native and cleaved
forms of the inhibitors but readily internalizes the proteinase
complexed form of the inhibitors. Taken together, these data
suggest that the liver receptor responsible for the plasma clear-
ance of ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin is
LRP.
To demonstrate this, in vivo clearance studies were per-
formed in rats. The ability of RAP to inhibit hepatic clearance
of ATIII-125I-thrombin indicates that a RAP-sensitive hepatic
receptor is responsible for this process. While RAP is known to
bind to all members of the LDLR superfamily, only two of these
receptors, LDLR and LRP, are known to be expressed in high
levels in the liver. Our studies indicate that the LDLR does not
play a significant role in the catabolism of SECs, since PEA13
fibroblasts, which express LDLR and are normal in their ability
to catabolize LDL (Willnow and Herz, 1994; Kounnas et al.,
1995c), are unable to mediate the cellular catabolism of SECs.
Thus, the in vivo clearance studies suggest that LRP is playing
FIG. 6. LRP internalizes the proteinase complexed form of
125I-ATIII, 125I-HCII, and 125I-a1AT but not the native or modified
forms of the serpins.Mouse fibroblasts (2 3 105 cells/well) expressing
LRP (MEF) or lacking LRP (PEA13) were incubated for selected times
at 37 °C with 125I-labeled ATIII, HCII, or a1AT (5–10 nM, native, mod-
ified, or enzyme-complexed) in the presence and absence of RAP (1 mM).
At indicated intervals, the amount of radioligand internalized by the
cells was determined as detailed under “Experimental Procedures.”
Panels show the internalization of 125I-ATIII by MEF (A) and PEA13 (B)
cells, 125I-HCII by MEF (C) and PEA13 (D) cells, and 125I-a1AT by MEF
(E) and PEA13 (F) cells. Plotted values are means of duplicate values
and are representative of duplicate experiments.
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a prominent role in the hepatic clearance of SECs.
Perlmutter et al. (1990a, 1990b) described a SEC receptor on
monocytes and HepG2 cells which internalized complexes of
a1ATztrypsin and a1ATzelastase, and it is highly likely that this
receptor is LRP. In the present investigation, we found that the
cellular uptake and degradation of ATIIIzthrombin, HCIIz
thrombin, and a1ATztrypsin by Hep G2 cells is inhibited by
anti-LRP IgG. In addition to a receptor that mediates the
endocytosis of SECs, studies by several investigators suggest
that binding of SECs to the cell surface may result in signal
transduction events. Perlmutter et al. (1988) demonstrated
that binding of elastaseza1AT complexes to monocytes or
macrophages resulted in increased gene expression of a1AT,
while Banda et al. (1988) showed that cleaved a1AT stimulated
neutrophil chemotaxis. Hoffman et al. (1989) reported that
HCII could be cleaved by proteinases to generate products that
stimulated neutrophil chemotaxis, suggesting that cleaved ser-
pins release biologically active molecules. While the mecha-
nism of signal transduction by these complexes is unclear, it
seems likely that a distinct signaling receptor, different from
LRP, may exist and would account for these effects.
The existence of a clearance mechanism for SECs is likely
important since such complexes are known to dissociate with
time, releasing active enzyme along with the cleaved inhibitor
(Travis and Salvesen, 1983; Carrell and Boswell, 1986). ATIII
is a primary inhibitor of thrombin and FXa and plays a major
role in maintaining normal hemostasis (Bjork et al., 1989;
Olson and Bjork, 1992). Disruption of the normal balance of
thrombin and inhibitor activity results in either thrombosis
(Egeberg, 1965; Lane et al., 1991) or bleeding disorders (Owen
et al., 1983); therefore, it is clear that maintaining an appro-
priate amount of thrombin activity is critical for normal hemo-
stasis. The principle action of ATIII may be to localize clotting
by inhibiting thrombin that has escaped into the circulation,
and the LRP-mediated clearance of ATIIIzthrombin complexes
may serve to help maintain normal hemostasis.
The imbalance of a1AT/proteinase activity has been associ-
ated with various pathological conditions such as pulmonary
emphysema (Laurell and Eriksson, 1963; Travis and Salvesen,
1983; Carrell, 1986). a1AT has been implicated as a primary
modulator of elastase and proteinase 3 activity during inflam-
matory processes. In acute inflammation, infiltrating neutro-
phils and macrophages, as well as damaged cells, release ex-
cessive amounts of proteinases resulting in tissue damage. This
damage can be minimized by rapid inhibition of proteinase
activity by inhibitors present in body fluids. Elastase and PR3
are released by neutrophils during inflammation and partici-
pate in the degradation of extracellular matrix components.
FIG. 7. Comparison of uPAzPAI-1, a2M*, ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin degradation by mouse fibroblasts.
Mouse fibroblasts expressing LRP (2 3 105) were incubated with 125I-labeled ligand in the absence of competitor or in the presence of 1 mM RAP.
Following incubation, the amount of degraded (trichloroacetic-soluble) 125I-ligand secreted into the medium was measured. Degradation measured
in the presence of 1 mM RAP was subtracted from the amount of degradation measured in the absence of competitor. Panel A, 125I-labeled ligands
(1 nM) were incubated for 8 h at 37 °C. The data shown are an average of duplicate determinations 6 standard error. Panel B, 125I-ATIIIzthrombin
(E), 125I-HCIIzthrombin (f), and 125I-a1ATztrypsin (M), at 0.6–150 nM, were incubated for 18 h at 37 °C. Panel C,
125I-uPAzPAI-1 (l; 0.6–15 nM)
was incubated for 18 h at 37 °C.
FIG. 8. RAP inhibits the clearance
of 125I-a2M* (A) and ATIIIz
125I-throm-
bin from the plasma of rats (B). A, a
bolus of 500 ml of 125I-a2M (10 nM) in the
absence (l) or presence (M) of RAP (32
mM) was injected into the tail vein of rats.
At the indicated times, blood (200 ml) was
collected into 10 ml of 0.5 M EDTA and an
aliquot (50 ml) was counted for its 125I
content. B, a bolus of 500 ml of ATIIIz125I-
thrombin (100 nM) in the absence (l) or
presence (M) of RAP (110 mM) was injected
into the tail vein of rats. At the indicated
times, blood (200 ml) was collected into 10
ml of 0.5 M EDTA and an aliquot (50 ml)
was counted for its 125I content. The clear-
ance of each preparation was examined in
two rats, and the data plotted represent
the average value 6 S.E.
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Once these enzymes are inhibited by a1AT, the complexes
formed are known to be cleared by macrophages and fibroblasts
in a receptor-mediated process. LRP is found in high concen-
tration on fibroblasts and macrophages (Moestrup et al., 1992)
and has been shown to bind and mediate the uptake of at least
two a1ATzproteinase complexes (Poller et al., 1995; this study)
and therefore is very likely to represent the receptor responsi-
ble for the endocytosis of a1ATzproteinase complexes formed
during the inflammatory response.
Comparative experiments demonstrated that several higher
affinity LRP ligands such as uPAzPAI-1 and a2M* were inter-
nalized and subsequently degraded to a greater extent than
complexes of ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin.
This is likely related to the weaker affinity of these latter
ligands for LRP. Interestingly, the affinity for the interaction of
ligands with LRP varies considerably: uPAzPAI-1 (,1 nM; Nyj-
kaer et al. (1994)), a2Mzmethylamine (10 nM; Ashcom et al.
(1990)), LpL (18 nM; Chappell et al. (1992)), thrombospondin
(3–20 nM; Mikhailenko et al. (1995)), pro-uPA (45 nM; Kounnas
et al. (1993)), PAI-1 (55 nM; Nykjaer et al. (1994)), hepatic lipase
(52 nM; Kounnas et al. (1995a)), apoE (54 nM; Kounnas et al.
(1995b)), amyloid precursor protein (80 nM; Kounnas et al.
(1995c)), and approximately 80–120 nM for the complexes of
ATIIIzthrombin, HCIIzthrombin, and a1ATztrypsin. The rela-
tively lower affinity of LRP for the SECs (ATIIIzthrombin,
HCIIzthrombin, and a1ATztrypsin) as compared to other li-
gands may be compensated for during conditions of thrombosis
or inflammation where the plasma or interstitial fluid levels of
complexes are greatly elevated. Other factors may also aug-
ment LRP-mediated uptake of the SECs. For example cell-
surface proteoglycans, which have been shown to facilitate the
uptake of a number of LRP ligands including lipoprotein lipase
(Chappell et al., 1993), hepatic lipase (Kounnas et al., 1995),
and thrombospondin (Mikhailenko et al., 1995), may act to
concentrate SECs on the surface of LRP-expressing cells and
thereby increase their local concentration.
In summary, the current investigation demonstrates that
LRP can bind and endocytose complexes of ATIIIzthrombin,
HCIIzthrombin, and a1ATztrypsin, but not the native or the
cleaved inhibitors. In vivo clearance studies confirm that LRP
functions to remove SECs from the plasma. These findings
expand the role of LRP as a SEC receptor.
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